Lakewood-Amedex Biotherapeutics has received all necessary Institutional Review Board approvals and confirmed site readiness to begin its Phase 2a clinical trial of Nu-3, a novel topical gel aimed at treating mildly infected diabetic foot ulcers (iDFU). This trial builds on promising preclinical safety and efficacy data, targeting drug-resistant wound infections that cause significant health issues including amputations. Nu-3 uses a unique mechanism to combat bacteria and reduce antimicrobial resistance, aligning with federal efforts to fight antibiotic resistance. The trial is led by expert Dr. David G. Armstrong and aims to improve patient outcomes in a condition affecting millions worldwide.
Lakewood-Amedex Biotherapeutics clinical trial news is context for health sector data. For readers following health stocks, here is Pluang's market snapshot as of Sep 18, 2026 18:41 WIB: 92 US health stocks were priced, with 39 rising and 42 falling. Notable movers include CTXR at USD 0.60 with 100% sell orders, DNA at USD 7.98 with 100% buy orders, and TXG at USD 78.30 also with 100% buy orders. Typical hold times range from 11 to 94 days among these stocks.
U.S. spot ETFs for XRP have drawn about $1.71 billion in net inflows, holding $1.39 billion in assets, signaling strong institutional interest. Despite this, XRP trades around $1.33, about 64% below its all-time high of $3.65, due to broader market s...
Following the Federal Reserve's recent quarter-point rate hike, stocks and bonds rallied with major indexes posting their strongest gains in over six weeks. The 10-year Treasury yield dropped below 5%, while easing oil prices helped reduce inflation ...
The First Trust Nasdaq Semiconductor ETF (FTXL) delivered a strong one-year return of 119.6%, outperforming major semiconductor ETFs like SOXX and SMH by over 18%. This outperformance is attributed to FTXL's unique factor-driven, cash-flow-weighted a...
Four major US-listed tobacco companies—Altria Group, Philip Morris International, British American Tobacco, and Universal Corporation—are generating substantial operating cash flow with minimal capital expenditures. This allows them to pay high divid...
Hyperliquid Strategies (PURR) shares rose about 8% following the SEC's announcement of a five-year 'Innovation Exemption' that permits tokenized U.S. stock trading on public blockchain networks via automated market makers. This regulatory relief requ...
